Resources from the same session
LBA8 - Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
Presenter: Toni Choueiri
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8
Presenter: Sumanta Pal
Session: Presidential Symposium III
Resources:
Slides
Webcast
LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)
Presenter: Chris Parker
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA9
Presenter: Silke Gillessen
Session: Presidential Symposium III
Resources:
Slides
Webcast
LBA10 - Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
Presenter: Melissa Johnson
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA11 - IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Presenter: Siow Ming Lee
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Presidential Symposium III
Resources:
Slides
Webcast